Expansion Opportunity Novacyt is actively growing through acquisitions and partnerships, including a planned acquisition of Southern Cross Diagnostics and a five-year collaboration with Illumina. This indicates appetite for expanded product portfolios and co-developed solutions, suggesting sales opportunities to cross-sell instrumentation, reagents, and integrated workflows that complement existing Genomics and molecular diagnostics offerings.

Infectious Disease Focus With a leadership position in infectious disease and a broad portfolio of molecular assays and workflows, there is a strong opportunity to position tools and services aimed at infectious disease monitoring, pathogen detection, and surveillance, including scalable laboratory automation and data analytics solutions that integrate with their current genomic medicine focus.

Regulatory Milestone The launch of an IVDR CE-marked DPYD assay demonstrates ongoing regulatory-driven product development. This signals readiness for more compliant, internationalized product lines and potential upsell of regulatory consulting, quality management, and compliant packaging or translation services to support global market deployment.

Leadership and Talent Shifts Recent leadership changes at the Chief Scientific Officer and Chief Business Officer levels may create near-term strategic pivots and renewed focus areas. This can present a window to offer strategic partnerships, consulting, or co-development opportunities aligned with new leadership priorities and go-to-market strategies.

Financial and Partnership Readiness Despite a modest revenue band, the company has substantial funding and a track record of high-velocity deals, suggesting readiness to explore larger contract manufacturing, distribution partnerships, or value-added reselling agreements, particularly in markets where Illumina collaboration or existing distributor networks can be leveraged to accelerate sales.